壹石通(688733.SH):擬定增募資不超9.51億元 用於年產15000噸電子功能粉體材料建設項目等
格隆匯2月25日丨壹石通(688733.SH)公佈2022年度向特定對象發行A股股票預案,此次發行的股票數量不超過此次發行前公司總股本的30%,即此次發行的股票數量不超過5464.93萬股(含本數),最終發行數量上限以中國證監會同意註冊的發行數量上限為準。
此次發行的募集資金總額不超過人民幣9.51億元(含本數),扣除發行費用後,擬3.53億元用於年產15,000噸電子功能粉體材料建設項目、擬2.22億元用於年產20,000噸鋰電池塗覆用勃姆石建設項目、擬1.96億元用於技術研發中心建設項目、擬1.8億元用於補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.